Revvity Surges to 435th in Market Rankings with $196 Million Turnover

On April 28, 2025, Revvity (RVTY) saw a significant surge in trading volume, with a turnover of $196 million, marking a 49.96% increase from the previous day. This substantial rise placed Revvity at the 435th position in the day's stock market rankings, reflecting a notable 0.82% increase in its stock price.

Revvity recently announced its financial results for the first quarter of 2025, reporting a revenue of $665 million, which represents a 2% reported growth and a 4% organic growth. The company's GAAP earnings per share (EPS) stood at $0.35, showing a year-over-year increase from $0.21.

The company's adjusted earnings per share for the quarter were $1.01, surpassing analysts' estimates. This performance was driven by strong contributions from both the Life Sciences and Diagnostics segments. The Life Sciences segment generated $340 million in revenue, with an adjusted operating income of $106 million. The Diagnostics segment reported $324 million in revenue, with an adjusted operating income of $74 million.

Revvity's financial update also highlighted a strong cash position, with $1.14 billion in cash and cash equivalents at the end of the first quarter. The company's net cash used in operating activities was $134.1 million, down from $150.1 million in the previous year. Revvity has reiterated its earnings outlook for 2025, expecting adjusted EPS to be in the range of $4.90-$5.00, with revenues anticipated to be between $2.83-$2.87 billion.